Perspective Therapeutics (CATX) Long-Term Debt Issuances (2010 - 2026)
Perspective Therapeutics (CATX) reported Long-Term Debt Issuances of $15000.0 for Q1 2026, up 15.38% on a YoY basis from $13000.0 in Q1 2025, and up 15.38% sequentially from $13000.0 in Q4 2025.
Perspective Therapeutics (CATX) Long-Term Debt Issuances (2010 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 6 years of Long-Term Debt Issuances data on file, last reported at $15000.0 in Q1 2026.
- For the quarter ending Q1 2026, Long-Term Debt Issuances rose 15.38% year-over-year to $15000.0; the trailing twelve-month figure through Mar 2026 stood at $54000.0 (up 10.2% YoY), and the FY2025 full-year result was $52000.0, up 8.33% from the prior year.
- Long-Term Debt Issuances rose to $15000.0 in Q1 2026, from $13000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $21000.0 in Q3 2023 to a low of $8000.0 in Q2 2024.
- A 4-year average of $14076.9 and a median of $13000.0 in 2025 frame the typical range for Long-Term Debt Issuances.
- Across the five-year window, Long-Term Debt Issuances slumped 60.0% in 2024 and jumped 62.5% in 2025, its largest moves.
- Tracing CATX's Long-Term Debt Issuances over 4 years: stood at $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024, then rose by 8.33% to $13000.0 in 2025, then climbed by 15.38% to $15000.0 in 2026.
- Business Quant data shows CATX's Long-Term Debt Issuances at $15000.0 in Q1 2026, $13000.0 in Q4 2025, and $13000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 19.86 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 11.71 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 1.15 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | 15,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Mar 31, 2025 | 13,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |
| Dec 31, 2023 | 12,000.00 |